Background
Materials and methods
Clinical data
Hematoxylin and eosin (H&E) stain and immunohistochemistry (IHC)
Specimen collection, DNA extraction and tumor specimen preparation
Sodium bisulfite modification of DNA
Methylation detection
CPG1 | |
CZ-G1-F1 | ATAGGGAATGGTTGAGTTTATTGT |
CZ-G1-R1-Bio | Biotin-ACCCCCTCTCCTCTACCATA |
CZ-G1-S1 | GTTTTTTGTAGTTTTTGAGA |
CZ-G1-S2 | AGTTTTTTTTTAGAATAAAG |
CZ-G1-S3 | TTTAGGAGTTTGAAGGG |
CZ-G1-S4 | GTTTAGGGTTTGGGGA |
CZ-G1-S5 | GGGAATGGTTGAGTTTA |
CPG2 | |
CZ-G2-F2 | AGGGTTTGGGGATTTTAGTAGGT |
CZ-G2-R2-Bio | Biotin-TCCCCAAAATAAAAACATCAACT |
CZ-G2-S6 | TAGAGTTATGGTAGAGGAGAG |
Statistical methods
Results
Clinical results
Items | PMLP | PCa with LN (−) | PCa with LN (+) |
---|---|---|---|
No. of cases | 10 | 10 | 10 |
Median age (y, range) | 69 (57–82) | 67 (46–79) | 68 (52–83) |
Mean PSA (ng/ml, range) | 2.8 (0.54–4.82) | 12.63 (8.86–38.46) | 16.86 (10.07–87.22) |
Mean LDH (U/l, range) | 320.4 (153–560) | – | – |
Biopsy Gleason sum n | |||
≤ 6 | – | 3 | 1 |
3 + 4 | – | 3 | 3 |
4 + 3 | – | 2 | 3 |
8–10 | – | 2 | 3 |
Pathological Gleason sum n | |||
≤ 6 | – | 2 | 0 |
3 + 4 | – | 2 | 2 |
4 + 3 | – | 3 | 4 |
8–10 | – | 3 | 4 |
Pathological T stage n | |||
T2a | 0 | 2 | 0 |
T2b | 4 | 2 | 0 |
T2c | 5 | 5 | 0 |
≥ T3a | 1 | 1 | 10 |
Lymph node invasion n | |||
Negative | 10 | 10 | 0 |
Positive | 0 | 0 | 10 |
CT or MRI
Pathological results
Surgical procedures | Pathological types | Immunophenotype | |
---|---|---|---|
1 | TURP | DLBCL | CK(−), LCA(+), CD45RO(−), CD20(+), CD79a(+), CyclinD1(−), CD10(−), MUM1(+), Bcl2(+), Bcl6(+), CD30(−), Ki-67(70% +) |
2 | TURP | DLBCL | CK(−), LCA(+), CD3(−), CD20(+), CD79a(+), CD5(−), CyclinD1(−), CD10(−), MUM1(+), Bcl2(+), Bcl6(+), Ki-67(55% +) |
3 | LRP | DLBCL | CK(−), LCA(+), CD3(−), CD45RO(−), CD20(+), CD79a(+), CyclinD1(−), CD10(+), CD30(−), Ki-67(40%) |
4 | TURP | MCL | CK(−), LCA(+), CD3(−), CD20(+), CD79a(+), CD5(+), CyclinD1(+), CD10(−), MUM1(+), Bcl2(+), Bcl6(−), CD30(−), Ki-67(30%) |
5 | LRP | DLBCL | CK(−), LCA(+), CD3(−), CD20(−), CD79a(+), CD5(−), CyclinD1(−), CD10(−), MUM1(−), Bcl2(+), Bcl6(+), CD30(−), Ki-67(90% +) |
6 | TURP | DLBCL | CK(−), LCA(+), CD45RO(−), CD20(+), CD79a(+), CD5(−), CyclinD1(−), CD10(−), MUM1(+), Bcl2(+), Ki-67(80% +) |
7 | TURP | DLBCL | CK(−), LCA(+), CD45RO(−), CD20(+), CD79a(+), CyclinD1(−), CD10(+), MUM1(−), Bcl2(+), Ki-67(80% +) |
8 | LRP | DLBCL | CK(−), LCA(+), CD45RO(−), CD20(−), CD79a(+), CD5(−), CyclinD1(−), CD10(+), MUM1(−), Bcl2(+), Bcl6(+), Ki-67(45% +) |
9 | TURP | DLBCL | CK(−), LCA(+), CD3(−), CD20(+), CD79a(+), CD5(−), CyclinD1(−), CD10(−), MUM1(−), Bcl2(+), Bcl6(+), CD30(−), Ki-67(80% +) |
10 | LRP | DLBCL | CK(−), LCA(+), CD45RO(−), CD20(−), CD79a(+), CD5(−), CyclinD1(−), CD10(−), MUM1(+), Bcl2(+), Bcl6(−), Ki-67(35% +) |
CRMP4 methylation in the promotor region
ROC curve analyzing the value of CRMP4 methylation in predicting PMLP
Criterion | Sensitivity | 95% CI | Specificity | 95% CI | Sensitivity + specificity |
---|---|---|---|---|---|
≥ 13.2 | 100 | 69.2–100.0 | 0 | 0.0–16.8 | 100 |
> 30.1 | 90.0 | 55.5–99.7 | 70.0 | 45.7–88.1 | 160.0 |
> 39.4 | 90.0 | 55.5–99.7 | 85.0 | 62.1–96.8 | 175.0 |
> 40.9 |
90.0
|
55.5–99.7
|
95.0
|
75.1–99.9
|
185.0
|
> 41.4 | 80.0 | 44.4–97.5 | 95.0 | 75.1–99.9 | 175.0 |
> 42 | 70.0 | 34.8–93.3 | 100 | 83.2–100.0 | 170.0 |
> 44.8 | 30.0 | 6.7–65.2 | 100 | 83.2–100.0 | 130.0 |
> 48.6 | 0 | 0.0–30.8 | 100 | 83.2–100.0 | 100 |
Group | Wilcoxon Z | DSCF-value | P value |
---|---|---|---|
PMLP vs LPCa | 3.74 | 5.29 | < 0.001 |
PMLP vs LPCa-LN (−) | 3.78 | 5.35 | < 0.001 |
PMLP vs mPCa | 3.33 | 4.70 | 0.01 |
PMLP vs mPCa-LN (+) | 3.78 | 5.35 | < 0.001 |
LPCa vs LPCa-LN (−) | 3.78 | 5.35 | < 0.001 |
LPCa vs mPCa | − 1.74 | 2.46 | 0.41 |
LPCa vs LPCa-LN (+) | 1.06 | 1.50 | 0.83 |
LPCa-LN (−) vs mPCa | − 3.78 | 5.35 | < 0.001 |
LPCa-LN (−) vs LPCa-LN (+) | − 3.78 | 5.35 | < 0.001 |
mPCa vs LPCa-LN (+) | 1.36 | 1.93 | 0.65 |